Grant: Master's Award: Canada Graduate Scholarships
McMaster University
$17,500.00
Estimating prognosis among advanced heart failure patients referred for advanced heart failure therapies
FY 2020-21
Summary
This single-center retrospective cohort study aims to evaluate the accuracy and potential clinical impact of existing and newly derived risk prediction models to estimate 1-year mortality risk in patients undergoing assessment for advanced heart failure (HF) therapies. In light of the increasing prevalence of HF, and high associated mortality rate, advanced HF patients are often considered for advanced therapies, namely ventricular assist device or heart transplant. These therapies aim to improve quality of life and patient survival but are costly and associated with serious risk. Given the clinical complexity of this patient population, evaluating prognosis for advanced HF patients is very challenging. Predictive models may offer important advantages to help physicians when evaluating the risk of mortality and candidacy for advanced HF therapies. I plan to conduct a retrospective analysis to 1) evaluate the accuracy of existing risk models for predicting risk of mortality among adults with advanced HF; 2) determine if a new risk model, developed using a larger scope of clinical data results in more accurate prognostic estimates; (3) evaluate the impact of using the best performing model among HF patients deemed adequate and inadequate candidates for advanced HF therapies; and (4) evaluate the clinical benefit of these therapies for patients considered appropriate candidates. This study will inform future guidelines and practices for assessing risk in advanced HF patients. By developing a more powerful risk prediction model, we hope to improve prognostic accuracy in this high-risk population, better identify who should receive advanced therapies, and optimize donor organ allocation and healthcare resources in Canada.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
449681
Name
Buchan Tayler
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Estimating prognosis among advanced heart failure patients referred for advanced heart failure therapies
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cardiac; Heart Failure; Heart Transplant; Prediction; Prognosis; Survival
Abstract
This single-center retrospective cohort study aims to evaluate the accuracy and potential clinical impact of existing and newly derived risk prediction models to estimate 1-year mortality risk in patients undergoing assessment for advanced heart failure (HF) therapies. In light of the increasing prevalence of HF, and high associated mortality rate, advanced HF patients are often considered for advanced therapies, namely ventricular assist device or heart transplant. These therapies aim to improve quality of life and patient survival but are costly and associated with serious risk. Given the clinical complexity of this patient population, evaluating prognosis for advanced HF patients is very challenging. Predictive models may offer important advantages to help physicians when evaluating the risk of mortality and candidacy for advanced HF therapies. I plan to conduct a retrospective analysis to 1) evaluate the accuracy of existing risk models for predicting risk of mortality among adults with advanced HF; 2) determine if a new risk model, developed using a larger scope of clinical data results in more accurate prognostic estimates; (3) evaluate the impact of using the best performing model among HF patients deemed adequate and inadequate candidates for advanced HF therapies; and (4) evaluate the clinical benefit of these therapies for patients considered appropriate candidates. This study will inform future guidelines and practices for assessing risk in advanced HF patients. By developing a more powerful risk prediction model, we hope to improve prognostic accuracy in this high-risk population, better identify who should receive advanced therapies, and optimize donor organ allocation and healthcare resources in Canada.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Buchan, Tayler
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~